Bioresponsive engineered nanoparticles for immunomodulation
Nanomaterials possess significant immunomodulatory capabilities, enhancing both disease prevention and therapeutic efficacy in vivo, yet their clinical translation is hindered by complex fabrication methods and high production costs. Future efforts must focus on simplifying synthesis and improving cost-efficiency to facilitate their adoption in clinical practice.
Authors
- Muthu K. Shanmugam (ORCID: https://orcid.org/0000-0002-8314-9227)
- Mangala Hegde (ORCID: https://orcid.org/0000-0003-2926-896X)
- Gautam Sethi (ORCID: https://orcid.org/0000-0002-8677-8475)
- Ajaikumar B. Kunnumakkara (ORCID: https://orcid.org/0000-0001-9121-6816)
- Chester Lee Drum (ORCID: https://orcid.org/0000-0001-6327-4584)
- Le Liu (ORCID: https://orcid.org/0000-0002-9270-9951)
- Mohammed S. Alqahtani (ORCID: https://orcid.org/0000-0002-5027-6545)
- Anamika Mishra
- Mohamed Abbas
- Ruchira Banerjee
- Bintee Bintee
Institutions
- Indian Institute of Technology Guwahati (IN)
- University of Leicester (GB)
- National University of Singapore (SG)
- National University Cancer Institute, Singapore (SG)
- Zhujiang Hospital (CN)
- King Khalid University (SA)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-10-30
- DOI
- https://doi.org/10.1186/s12916-025-04305-6
- Citations
- 5
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 3.37
Funders
- Department of Biotechnology, Ministry of Science and Technology, India
- National Natural Science Foundation of China
- Indian Institute of Technology Guwahati
- National Medical Research Council